ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Findings from a federal study of more than 53,000 current or former heavy smokers further confirm the potential of cancer diagnostics company Biomoda, Inc.’s non-invasive, inexpensive CyPath® assay for the detection of early-stage lung cancer.
